Skip to main content

Advertisement

SpringerLink
Log in

The Role of Liposomal Anthracyclines in Metastatic Breast Cancer

  • Systemic Therapy (J Cortes, Section Editor)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Anthracyclines (doxorubicin and epirubicin) have traditionally occupied a central place in the treatment of early and advanced breast cancer. In patients with metastatic breast cancer (MBC), anthracycline containing regimens have been shown to be superior in terms of activity and efficacy to non antharcycline containing regimens. However, the incidence of cardiac toxicity related to conventional anthracycline use prevents their administration especially in advanced disease, where higher cumulative doses are needed due to the wide use of these agents in the adjuvant setting. In more recent years, new liposomal formulations of doxorubicin, mainly non pegylated doxorubicin (NPLD) and pegylated doxorubicin (PLD), were developed and are now available for clinical use in MBC. Both agents showed a level of activity and efficacy similar to conventional anthracyclines in head to head comparisons, with an improved cardiac safety profile. This peculiarity also led to the development of very active and safe combinations with trastuzumab in HER-2 positive disease, opening new treatment scenarios in this setting. This review summarizes available evidence on the use of liposomal anthracyclines in advanced breast cancer, including HER-2 positive disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Recently published papers of particular interest have been highlighted as: • Of importance •• Of major importance

  1. Lord S, Ghersi D, Gattellari M, et al. Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2004.

  2. •• Airoldi M, Amadori D, Barni S, et al. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori. 2011;97:690–2. This is a comprehensive review on NPLD use in MBC with a focus on cardiac safety.

  3. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26:1980–6.

    Article  PubMed  CAS  Google Scholar 

  4. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39–51.

    Article  PubMed  CAS  Google Scholar 

  5. Mayer L, Nohria A, Miller K, Rugo H, Carey L, Ryabin N, et al. Cardiovascular safety of adjuvant bevacizumab for breast cancer. Proc Am Soc Clin Oncol. 2010;Abstract 571.

  6. Martin F, Boulikas T. The challenge of liposomes in gene therapy. Gene Ther Mol Biol. 1998;1:173–214.

    Google Scholar 

  7. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25–36.

    Article  PubMed  CAS  Google Scholar 

  8. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444–54.

    PubMed  CAS  Google Scholar 

  9. Batist G, Harris L, Azarnia N, et al. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs. 2006;17:587–95.

    Article  PubMed  CAS  Google Scholar 

  10. Chan S, Davidson N, Juozaityte E, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004;15:1527–34.

    Article  PubMed  CAS  Google Scholar 

  11. •• Van Dalen EC, Michiels EM, Caron HN, et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2006;4:CD005006. Update in: Cochrane Database Syst Rev. 2010. This is a review on the differential cardiotoxic profile of conventional anthracyclines and liposomal formulations.

  12. Nabholtz J-M, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21:968–75.

    Article  PubMed  CAS  Google Scholar 

  13. Luck HJ, Thomssen C, Untch M, et al. Multicentric phase II study in first-line treatment of advanced metastatic breast cancer (ABC). Epirubicin/Paclitaxel (ET) vs Epirubicin/Cyclophosphamide (EC). A study of the Ago Breast Cancer Group. Proc Am Soc Clin Oncol. 2000; Abstract 280.

  14. Bonneterre J, Dieras V, Tubiana-Hulin M, et al. Phase II multicenter randomized study of docetaxel plus epirubicin vs 5-Fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer. 2004;91:1466–71.

    PubMed  CAS  Google Scholar 

  15. Bontenbal M, Braun JJ, Creemers GJ, et al. Phase II to III study comparing doxorubicin and docetaxel with 5-Fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol. 2005;23:7081.

    Article  PubMed  CAS  Google Scholar 

  16. Biganzoli L, Cufer T, Bruning P. Doxorubicin and paclitaxel vs doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: EORTC 10961. J Clin Oncol. 2002;20:3114–21.

    Article  PubMed  CAS  Google Scholar 

  17. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel vs Fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 2001;19:1707–15.

    PubMed  CAS  Google Scholar 

  18. Schmid J, Krocker R, Kreienberg P, et al. Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial. Cancer Chemother Pharmacol. 2009;64:401–6.

    Article  PubMed  CAS  Google Scholar 

  19. Rosati M, Raimondi C, Baciarello G, et al. Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALt trial (phase I–II). Ann Oncol. 2011;22:315–20.

    Article  PubMed  CAS  Google Scholar 

  20. Curtit E, Nouyrigat P, Dohollou N, et al. Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. Eur J Cancer. 2011;47:2396–402.

    Article  PubMed  CAS  Google Scholar 

  21. Theodoulou M, Batist G, Campos S, et al. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer. 2009;9:101–7.

    Article  PubMed  CAS  Google Scholar 

  22. • Cortes J, Di Cosimo S, Climent MA, et al. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res. 2009;15:307–14. This is a phase II trial on the combination of NPLD and trastuzumab, showing the feasibility and antitumor efficacy in advanced breast cancer.

  23. Venturini M, Bighin C, Puglisi F, et al. A multicenter Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast. 2010;19:333–8.

    Article  PubMed  CAS  Google Scholar 

  24. Amadori D, Milandri C, Comella G, et al. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel, and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer. Eur J Cancer. 2011;47:2091–8.

    Article  PubMed  CAS  Google Scholar 

  25. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996;36:55–63.

    PubMed  CAS  Google Scholar 

  26. O'Brien ME, Wigler N, Inbar M, et al. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) vs conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440–9.

    Article  PubMed  Google Scholar 

  27. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, et al. Randomized phase III trial of pegylated liposomal doxorubicin vs vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004;22:3893–901.

    Article  PubMed  CAS  Google Scholar 

  28. Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, et al. A randomized phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006;42:882–7.

    Article  PubMed  CAS  Google Scholar 

  29. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol. 2007;18:1159–64.

    Article  PubMed  CAS  Google Scholar 

  30. Vorobiof DA, Rapoport BL, Chasen MR, et al. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicenter phase II study. Breast. 2004;13:219–26.

    Article  PubMed  CAS  Google Scholar 

  31. Alexopoulos A, Karamouzis MV, Stavrinides H, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol. 2004;15:440–9.

    Article  Google Scholar 

  32. Rivera E, Valero V, Arun B, et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol. 2003;21:3249–54.

    Article  PubMed  CAS  Google Scholar 

  33. Fabi A, Ferretti G, Papaldo P. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naive and anthracycline pretreated metastatic breast cancer patients. Cancer Chemother Pharmacol. 2006;57:615–23.

    Article  PubMed  CAS  Google Scholar 

  34. Sparano JA, Malik U, Rajdev L, et al. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol. 2001;19:3117–25.

    PubMed  CAS  Google Scholar 

  35. Morabito A, Gattuso D, Stani SC, et al. Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer Res Treat. 2004;86:249–57.

    Article  PubMed  CAS  Google Scholar 

  36. Jones V, Finucane D, Rodriguez R, et al. Phase II study of weekly paclitaxel (Taxol) and liposomal doxorubicin (Doxil) in patients with locally advanced and metastatic breast cancer. Proc Am Soc Clin Oncol. 2000;21:113a:Abstract 451.

  37. Chia S, Clemons M, Martin LA, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol. 2006;24:2773–8.

    Article  PubMed  CAS  Google Scholar 

  38. Andreopoulou E, Gaiotti D, Kim E, et al. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2007;7:690–6.

    Article  PubMed  CAS  Google Scholar 

  39. Christodoulou C, Kostopoulos I, Kalofonos HP, et al. Study of the Hellenic Cooperative Oncology Group. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Oncology. 2009;76(4):275–85.

    Article  PubMed  CAS  Google Scholar 

  40. Stickeler AE, Maximilian K, Watermann D, et al. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Res Treat. 2009;117:591–8.

    Article  PubMed  CAS  Google Scholar 

  41. Martín M, Sánchez-Rovira P, Muñoz M, et al. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–2005 study. Ann Oncol. 2011;22:2591–6.

    Article  PubMed  Google Scholar 

  42. Rochlitz C, Ruhstaller T, Lerch S, et al. Combination of bevacizumab and 2 - weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol. 2011;22:80–5.

    Article  PubMed  CAS  Google Scholar 

  43. Morabito A, Piccirillo MC, Monaco K, et al. First-line chemotherapy for HER-negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment. Oncologist. 2007;12:1288–98.

    Article  PubMed  CAS  Google Scholar 

  44. Kardinal CG, Perry MC, Korzun AH, et al. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081. Cancer. 1988;61:415–9.

    Article  PubMed  CAS  Google Scholar 

  45. Venturini M, Bruzzi P, Del Mastro L, et al. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol. 1996;14:764–73.

    PubMed  CAS  Google Scholar 

  46. Pierga JY, Robain M, Jouve M, et al. Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients. Ann Oncol. 2001;12:231–7.

    Article  PubMed  CAS  Google Scholar 

  47. Gennari A, Bruzzi P, Orlandini C, et al. Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer. 2004;90:962–7.

    Article  PubMed  CAS  Google Scholar 

  48. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–7.

    Google Scholar 

  49. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep. 1979;63:827–34.

    PubMed  CAS  Google Scholar 

  50. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109–18.

    Article  PubMed  CAS  Google Scholar 

  51. Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997;54 Suppl 4:1–7.

    Article  PubMed  Google Scholar 

  52. Al-Batran SE, Guntner M, Pauglik C, et al. Antrhacyclines rechallenge using pegylate liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. Br J Cancer. 2010;103:1518–23.

    Article  PubMed  CAS  Google Scholar 

  53. Al-Batran SE, Bischoff J, von Minckwitz G, et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicenter phase II trial. Br J Cancer. 2006;94:1615–20.

    PubMed  CAS  Google Scholar 

  54. Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70:141–6.

    Article  PubMed  CAS  Google Scholar 

  55. Safra F, Muggia S, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/ m2. Ann Oncol. 2000;11:1029–33.

    Article  PubMed  CAS  Google Scholar 

  56. • Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29:2144–9. This paper demonstrates a benefit in overall survival with prolonged first line chemotherapy administration.

  57. Alba E, Ruiz-Borrego M, Margelí M, et al. Maintenance treatment with pegylated liposomal doxorubicin vs observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001–01 study. Breast Cancer Res Treat. 2010;122:169–76.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Galliera Hospital, Via Volta, 6, Genoa, Italy

    Alessandra Gennari

  2. Division of Cardiology, Galliera Hospital, Via Volta, 6, Genoa, Italy

    Marco Piccininno

  3. IRST, Romagna Cancer Institute, Via Maroncelli, Meldola, Forlì, Italy

    Samanta Sarti

Authors
  1. Alessandra Gennari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Piccininno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samanta Sarti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandra Gennari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gennari, A., Piccininno, M. & Sarti, S. The Role of Liposomal Anthracyclines in Metastatic Breast Cancer. Curr Breast Cancer Rep 5, 23–30 (2013). https://doi.org/10.1007/s12609-012-0099-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-012-0099-z

Keywords

Search

Navigation